TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years
Brief Summary: This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years


Options:
A: Inclusion Criteria:

* Aged 18-35
* Body Mass Index (BMI) 19-24.9 or 30-39.9 kg/m\^2
* Willing to take birth control pills for 3-4 months
* Recent spontaneous pregnancy or cyclic menses

Exclusion Criteria:

* Contraindications to hormonal contraceptives
* Oophorectomy/Polycystic ovary syndrome (PCOS)
* Taken oral contraceptives to regulate menses recently
* Weight reduction surgery
* Used Depo-Provera within the last 12 months
* Pregnant or currently breastfeeding
* Desiring pregnancy within the next 4 months
* Unable to make study visit commitment
* Previous participation in this study
B: Inclusion Criteria:

* First-ever OC users ("starters")
* Women switching OC use without a pill intake break ("switchers")
* Recurrent users with a pill intake break ("recurrent users")
* Women willing to participate in the active surveillance

Exclusion Criteria:

* Women who do not agree to participate
* Long-term users
C: Inclusion Criteria:

* Age between 18 and 35 years (inclusive), in good general health and requesting contraception.
* Has regular menstrual cycles (length of cycle 21-35 days) (i.e., endogenous cyclicity without hormonal contraceptive use).

Exclusion Criteria:

* Known or suspected pregnancy or is lactating.
* History of ectopic pregnancies.
* Any genital infection (until successfully treated).
* Abnormal uterine bleeding of unknown origin.
D: Inclusion Criteria:

Healthy females

* 17(in states where the legal age of consent to receive contraceptives is 17)-40 years
* Regular, consistent menstrual cycles between 25 and 35 days
* Sexually active women requesting birth control
* In good general health, confirmed by medical history, physical (including gynecologic) examination and screening laboratory values

Exclusion Criteria:

* Known or suspected pregnancy;
* Lactating women
* Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
* Use of other contraceptive methods than study medication

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of Organisational Changes to Promote Smoking Cessation
Brief Summary: The Department of Family Practice at Michigan State University partnered with BCBSM with a grant from the Robert Wood Johnson Foundation to recruit primary care practices for a 3 year study designed to assess smoking cessation referral rates by primary care physicians in Michigan.


Options:
A: Inclusion Criteria:

* Participating Client
* Not Re-Enrolling
* USA Resident
* Wants to quit in the next 30 days
* Use Cigarettes (other types ok, but must use cigarettes)
* 18 years or older
* Speak English
* Provide Phone
* Provide Email Address
* Use 10 cigarettes per day or more
* BMI of 18.5 or above
* No history of anorexia or bulimia

Exclusion Criteria:

* Pregnant or Planning Pregnancy within 3 months
* Diabetic
* Previous weight loss surgery or planning weight loss surgery in next 12 months
B: Inclusion Criteria:

* Department of Defense healthcare beneficiary
* Has smoked five or more cigarettes per day for at least 1 year before study entry
* Must be at least eighteen years old

Exclusion Criteria:

* Known allergy or sensitivity to nicotine replacement therapy
* No telephone
* Inability to understand consent procedures
* Basic Military Trainee
C: DISEASE CHARACTERISTICS:

* Smokes 10 or more cigarettes/day over the past year AND ≥ 5 cigarettes/day within the past week
* Planning to stop smoking in 4-6 weeks
* Member of Group Health Cooperative (GHC) and planning to stay enrolled for the next 6 months
* Eligible for the Free \& Clear program
* Enrolled in the COMPASS study using bupropion hydrochloride medication
* No prior participation in GHC's Free \& Clear smoking cessation program within the past 6 months

PATIENT CHARACTERISTICS:

* In good general health
* Sufficient verbal and written English
* Dependable access to a telephone and the Internet
* Not currently drinking ≥ 14 alcoholic drinks per week and/or binge drinking ≥ 2 times in the past month
* Not pregnant or nursing
* No plan to become pregnant
* No severe chronic heart disease (e.g, myocardial infarction within the past 3 months)
* No severe chronic obstructive pulmonary disease that ever required hospitalization or oxygen treatment
* No diagnosis of or treatment for a psychotic disorder (e.g., schizophrenia, bipolar disorder, or mania)
* Not having certain kidney problems

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No concurrent use of medications contraindicated with bupropion hydrochloride or known to lower seizure threshold (e.g., antidepressant, antipsychotic, monamine oxidase inhibitor, or protease inhibitor)
* No concurrent use of recreational or street drugs
* No concurrent use of bupropion hydrochloride or nicotine replacement therapy
* No concurrent cimetidine, metformin, phenformin, pindolol, procainamide
* Not on dialysis
D: Inclusion Criteria:

* Primary care practice and thier Adult smokers

Exclusion Criteria:

* Non somkers

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Inclusion Criteria:

* Pregnancy between 36 and 42 weeks of gestation
* Live singleton
* Cephalic presentation
* A reassuring fetal heart rate pattern
* Bishop score greater than 6
* Inadequate uterine contraction (less than or equal to 2 per 10 minutes)

Exclusion Criteria:

* Nonreassuring fetal heart rate pattern
* Parity more than five
* Uterine scar
* Suspected placental abruption with abnormal fetal heart rate
* Vaginal bleeding other than "bloody show"
* Significant maternal cardiac, renal, or hepatic disease
* hypersensitivity to oxytocin, misoprostol or prostaglandin analogues
B: Inclusion Criteria:

* Indication for labour induction
* Term pregnancy with alive fetus
* Bishop score less than six

Exclusion Criteria:

* Age less than 18 years
* Previous uterine scar
* Nonvertex presentation
* Non-reassuring fetal status
* Fetal anomalies
* Fetal growth restriction
* Genital bleeding
* Tumors, malformations and/or ulcers of vulva, perineum or vagina
C: Inclusion Criteria:

* age 18 years old or more
* singleton pregnancy at 37 weeks gestation or more
* cephalic presentation
* reassuring fetal heart rate pattern
* admission for labor induction due to medical or obstetrical conditions
* bishop score less than 6
* giving consent and having signed the consent form for this study

Exclusion Criteria:

* parity more than 3
* estimated fetal weight more than 3,500 grams
* non-reassuring fetal heart rate pattern
* having contraindication for vaginal delivery
* previous uterine scar
* suspected abruptio placenta with non-reassuring fetal heart rate pattern
* abnormal bleeding per vagina, except bloody show
* PROM
* having underlying cardiac, hepatic, or renal diseases
* having history of allergy to misoprostol or prostaglandin analogues
* cervical dilatation 3 centimeters or more
* uterine contraction 3 times or more in 10 minute
D: Inclusion Criteria:

* 34 to 42 weeks of gestation
* live singleton
* Bishop score \< or = 6
* reassuring fetal heart beat pattern

Exclusion Criteria:

* nonreassuring fetal heart beat pattern
* parity ovr five
* any contraindication to labor and/or vaginal delivery
* uterine scar
* suspected placental abruption with abnormal FHR pattern
* vaginal bleeding other than "bloody show"
* cervical dilatation of \> or = 4 cm
* uterine contractions \> or = 3 in 10 minutes
* significant maternal cardiac, renal or hepatic disease
* hypersensitivity to misoprostol or prostaglandin analogs

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Inclusion Criteria:

* 34 to 42 weeks of gestation
* live singleton
* Bishop score \< or = 6
* reassuring fetal heart beat pattern

Exclusion Criteria:

* nonreassuring fetal heart beat pattern
* parity ovr five
* any contraindication to labor and/or vaginal delivery
* uterine scar
* suspected placental abruption with abnormal FHR pattern
* vaginal bleeding other than "bloody show"
* cervical dilatation of \> or = 4 cm
* uterine contractions \> or = 3 in 10 minutes
* significant maternal cardiac, renal or hepatic disease
* hypersensitivity to misoprostol or prostaglandin analogs
B: Inclusion Criteria:

* age 18 years old or more
* singleton pregnancy at 37 weeks gestation or more
* cephalic presentation
* reassuring fetal heart rate pattern
* admission for labor induction due to medical or obstetrical conditions
* bishop score less than 6
* giving consent and having signed the consent form for this study

Exclusion Criteria:

* parity more than 3
* estimated fetal weight more than 3,500 grams
* non-reassuring fetal heart rate pattern
* having contraindication for vaginal delivery
* previous uterine scar
* suspected abruptio placenta with non-reassuring fetal heart rate pattern
* abnormal bleeding per vagina, except bloody show
* PROM
* having underlying cardiac, hepatic, or renal diseases
* having history of allergy to misoprostol or prostaglandin analogues
* cervical dilatation 3 centimeters or more
* uterine contraction 3 times or more in 10 minute
C: Inclusion Criteria:

* Pregnancy between 36 and 42 weeks of gestation
* Live singleton
* Cephalic presentation
* A reassuring fetal heart rate pattern
* Bishop score greater than 6
* Inadequate uterine contraction (less than or equal to 2 per 10 minutes)

Exclusion Criteria:

* Nonreassuring fetal heart rate pattern
* Parity more than five
* Uterine scar
* Suspected placental abruption with abnormal fetal heart rate
* Vaginal bleeding other than "bloody show"
* Significant maternal cardiac, renal, or hepatic disease
* hypersensitivity to oxytocin, misoprostol or prostaglandin analogues
D: Inclusion Criteria:

* Clinical decision to augment labor
* Gestational age \> than or equal to 36 weeks
* Singleton gestation
* Cephalic presentation
* Reassuring fetal heart rate tracing
* Cervical dilation between 4 and 8 cm
* Ruptured membranes with clear amniotic fluid
* Intrauterine pressure catheter in place
* Less than 200 MVUs in a 10 minute period
* 5 or fewer contractions in a 10 minute period
* English or Spanish speaking patient

Exclusion Criteria:

* Non-reassuring fetal heart rate tracing at time of enrollment
* Meconium stained amniotic fluid
* Previous uterine incision
* Maternal fever (defined as greater than 37.9 C)
* Known fetal anomalies
* Placenta previa or unexplained vaginal bleeding
* Estimated fetal weight of 4,500 grams or more
* Abnormal maternal bony pelvis
* Grandmultiparity

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Inclusion Criteria:

* 34 to 42 weeks of gestation
* live singleton
* Bishop score \< or = 6
* reassuring fetal heart beat pattern

Exclusion Criteria:

* nonreassuring fetal heart beat pattern
* parity ovr five
* any contraindication to labor and/or vaginal delivery
* uterine scar
* suspected placental abruption with abnormal FHR pattern
* vaginal bleeding other than "bloody show"
* cervical dilatation of \> or = 4 cm
* uterine contractions \> or = 3 in 10 minutes
* significant maternal cardiac, renal or hepatic disease
* hypersensitivity to misoprostol or prostaglandin analogs
B: Inclusion Criteria:

* A medical indication for induction of labor at a gestational age between 37 +0 and 38 +6 weeks OR an elective or medical indication for induction of labor at a gestational age greater than or equal to 39 + 0 completed weeks
* Participant age of greater than or equal to14 years old
* Singleton pregnancy
* Modified Bishop score of less than or equal to 6
* Vertex fetal presentation by examination or ultrasound
* Any membrane status

Exclusion Criteria:

* Elective inductions between 37 +0 and 38 +6 completed weeks are specifically excluded
* Known intrauterine fetal demise
* Any uterine scar including prior cesarean section and myomectomy
* Known major fetal congenital malformations that may impact neonatal health
* Other evidence of fetal compromise (such as Category 2 or 3 tracing) before the induction begins
* Prior induction/cervical ripening methods utilized during this pregnancy
* Allergy to misoprostol
* Known untreated cervical infection (e.g. Gonorrhea, Chlamydia)
* Planned cesarean section due to maternal or fetal condition
* Any other contraindication to labor induction or misoprostol therapy
C: Inclusion Criteria:

* age 18 years old or more
* singleton pregnancy at 37 weeks gestation or more
* cephalic presentation
* reassuring fetal heart rate pattern
* admission for labor induction due to medical or obstetrical conditions
* bishop score less than 6
* giving consent and having signed the consent form for this study

Exclusion Criteria:

* parity more than 3
* estimated fetal weight more than 3,500 grams
* non-reassuring fetal heart rate pattern
* having contraindication for vaginal delivery
* previous uterine scar
* suspected abruptio placenta with non-reassuring fetal heart rate pattern
* abnormal bleeding per vagina, except bloody show
* PROM
* having underlying cardiac, hepatic, or renal diseases
* having history of allergy to misoprostol or prostaglandin analogues
* cervical dilatation 3 centimeters or more
* uterine contraction 3 times or more in 10 minute
D: Inclusion Criteria:

* Primigravida
* \>37 wks

Exclusion Criteria:

* Scarred uterus
* Macrosomia

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture vs. Traditional Treatment of Pain With Opioids
Brief Summary: Reducing pain is an essential factor for early mobilization after osteosynthesis of femoral neck fractures. Systemic opioids have side effects that might obstruct mobilization and induce delirium and nausea. The investigators hypothesized that wound infiltration results in reduction in systemic opioid usage and pain relief without side effects.


Options:
A: Inclusion Criteria:

- patients with femoral neck fracture in the emergency department

Exclusion Criteria:

* presence of demencia
* body weight less than 40kg
* presence of a cancer or patients receiving chemotherapy
* allergy to local anaesthetics
B: Inclusion Criteria:

* Adults age greater than or equal to 65 years old with acute hip fracture

Exclusion Criteria:

* ASA greater than or equal to 4
* Open fractures
* Other concomitant injuries that may interfere with positioning or pain scores
* Local anesthetic allergy
* Delirium at the time of consent
* Pre-existing cognitive impairment
* Infection at the site of injection for cFIB
* Previous surgery in femoral triangle
* Warfarin or Anti-Xa inhibitor use
* Long-term opioid use
* Intraoperative complications
C: Inclusion Criteria:

* Age 55 or older
* Sustaining either an OTA/AO type 31A or 31B fracture undergoing ORIF or hemiarthroplasty
* Able to consent
* Isolated injury

Exclusion Criteria:

* OTA/AO 31B1 (Impacted/slightly displaced)
* Baseline dementia or cognitive deficit
* Inability to consent
* Chronic Opioid use
* End stage liver disease with Model for End-Stage Liver Disease (MELD) greater than 20.
* End stage renal disease as defined by patients requiring hemodialysis at least twice weekly
* Polytrauma, defined as: concurrent upper or lower extremity fracture, pelvis fracture, spine fracture, rib fractures, or facial fractures, Blunt chest or abdominal trauma resulting in diagnosed organ injury, Head trauma resulting in intracranial bleed or diagnosed concussion
* Allergy to amide-type local anesthetics
* Prisoners (unlikely to be accessible for follow-up)
D: Inclusion Criteria:

* Femoral neck fracture
* Fracture due to low energy trauma
* Ability to understand danish and give informed consent
* Ability to walk before trauma
* Indication for osteosynthesis
* ≥ 8 in OMC (Orientation-Memory-Concentration) test with a possible maximum of 28 points
* Informed consent

Exclusion Criteria:

* Drug or medical abuse
* Drug intolerance
* Pathological fractures
* Inflammatory arthritis
* Patient included in the study with the contralateral hip

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol
Brief Summary: The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.


Options:
A: Participation as a volunteer in the Diabetes Prevention Program (DPP).
B: Inclusion Criteria:

* diagnosed for PCOS (Rotterdam criteria)
* aged 30-50 years
* safe non-hormonal contraception

Exclusion Criteria:

* use of cholesterol lowering agents
* use of antidepressants
* use of cortisone medication (p.o.)
* use of hormonal contraception
* nursing
* pregnancy
* DM-T2
* liver disease
* menopause
* kidney or liver failure
C: Inclusion Criteria:

* PCO - ESHRE/ASRM criteria:oligomenorrhea (\<8 spontaneus menses per year) and hyperandrogenism(hirsutism or acne) or hyperandrogenemia(testosterone \> 70 ng/ml) normal prolactin, TSH, 17-OH progesterone no evidence of androgen producing malignancy, Cushing's syndrome or acromegaly age 18-40 reliable use of birth control pill for at least 3 months and no plans of pregnancy

Exclusion Criteria:

* elevated creatinine kinase above 2 times upper limit of normal or liver enzymes (transaminase) above 2 times of upper limit of normal use of any following medications: cyclosporine, fibrates niacin,antifungal agents, macrolide antibiotics use of oral contraceptives and other steroid hormones 3 months prior to the study
D: Inclusion Criteria: Women with PCOS

* 8 or fewer menstrual periods per year
* elevated serum total testosterone
* elevated LDL cholesterol

Exclusion Criteria:

* current pregnancy or breastfeeding
* current use of oral contraceptives, progestins
* insulin sensitizing medications
* thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal
Brief Summary: The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission season: sulfadoxine-pyrimethamine (SP) plus amodiaquine, show to be highly effective for IPT in a recent trial; SP plus piperaquine, used for malaria prophylaxis in China for many years; or Duocotexcin (a combination of piperaquine with an artemisinin).


Options:
A: Inclusion Criteria:

* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)
* Student enrolled at participating school in classes 3-7
* Provision of informed consent from parent or guardian
* Provision of assent by student

Exclusion Criteria:

* Known allergy or history of adverse reaction to study medications
* Onset of menstruation (girls)
* Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours
* Evidence of severe malaria or danger signs
* Haemoglobin \< 7.0 gm/dL
* Parasite density \> 10,000/ul
B: Inclusion Criteria:

1. Age between 3 months and 59 months at enrolment.
2. Informed consent obtained from parents or legal guardians.
3. No current participation in another malaria intervention trial
4. Permanent residence in the study area with no intention of leaving during the surveillance period.

Exclusion Criteria:

1. Previous adverse reaction to treatment with SP, amodiaquine or Coartem. If this is unknown, then a history of allergic reaction to any drug.
2. Temporary residence in the study area
3. Lack of informed consent
4. Presence of a severe, chronic illness such as severe malnutrition or AIDS, likely to interfere with evaluation of the trial results.
C: Inclusion Criteria:

* Permanent residence in the study area with no intention of leaving during the surveillance period.
* Obtention of informed consent.

Exclusion Criteria:

* Temporary residence in the study area.
* Absence of informed consent.
* Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.
* A history of a previous, significant adverse reaction to either of the study drugs.
D: Inclusion Criteria:

* age 2 to 59 months in September 2007

Exclusion Criteria:

* history of allergy to study drugs

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal
Brief Summary: The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission season: sulfadoxine-pyrimethamine (SP) plus amodiaquine, show to be highly effective for IPT in a recent trial; SP plus piperaquine, used for malaria prophylaxis in China for many years; or Duocotexcin (a combination of piperaquine with an artemisinin).


Options:
A: Inclusion Criteria:

* age 2 to 59 months in September 2007

Exclusion Criteria:

* history of allergy to study drugs
B: Inclusion Criteria:

* Children between the ages of 3-59 months resident in the selected communities
* Children likely to be available for follow-up for 18 months
* Consent by parent/guardian of child

Exclusion Criteria:

* Chronic illness
* History of hypersensitivity to any of the study drugs
C: Inclusion Criteria:

* Informed consent
* Permanent residence in the study area

Exclusion Criteria:

* Allergy/hypersensitivity to sulfonamides or pyrimethamine
* Signs of severe hepatic or renal dysfunction not due to malaria
D: Inclusion Criteria:

* Enrolled in primary school, and attending regularly
* Enrolled in nursery or classes 1-7
* Informed consent from parent or guardian

Exclusion Criteria:

* Enrolled in primary class 8
* Haemoglobin level below 70g/L at baseline
* History of reaction to sulfa drugs (e.g. fansidar, septrin)
* History of severe skin reaction to any drug

Withdrawal criteria:

* Withdrawal of parental consent
* Haemoglobin level falling below 70g/L
* Severe adverse reaction to treatment

Answer: A